Anti-Eculizumab Polyclonal Antibody|抗依库珠单抗多克隆抗体(靶标：依库珠单抗（抗C5单抗）)
- 货号：RB9TAF687014
- 价格：面议
- 点击：489
产品介绍
产品参数
| 形态 | Liquid |
|---|---|
| 宿主种属 | Rabbit |
| 克隆性 | Polyclonal |
| 抗体亚型 | IgG |
| 纯化方式 | Purified by antigen affinity column. |
| 内毒素水平 | Please contact with the lab for this information. |
| 应用 | ELISA |
| 特异性 | The product is specific for Eculizumab. This antibody serves as an excellent positive control for Eculizumab immunogenicity (ADA) assays. |
| 靶标 | Rabbit polyclonal to Soliris. |
| 免疫原 | Eculizumab |
| 储存缓冲液 | 0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300. |
| 稳定性和储存 | The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles. |
| 产品使用说明 | ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000 |
| 登录号 | CAS: 219685-50-4 |
| 背景信息 | Eculizumab with trade name Soliris, is an FDA-approved drug to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica. Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5. Eculizumab specifically binds to the terminal complement component 5, or C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions. • Induction Immunosuppression in High-risk Kidney Transplant Recipients., PMID:27041548 • Acute Rejection Following Kidney Transplantation: State-of-the-Art and Future Perspectives., PMID:32520680 • The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts., PMID:22813834 |
| 备注 | For research use only. |
相关产品: